Review Article

Potential of Immunoglobulin A to Prevent Allergic Asthma

Anouk K. Gloudemans, Bart N. Lambrecht, and Hermelijn H. Smits

1 Department of Pulmonology, Erasmus Medical Center, Rotterdam, The Netherlands
2 Leiden Immunoparasitology Group, Department of Parasitology, Leiden University Medical Center, Albinusdreef 2, P4-37A, 2333 ZA Leiden, The Netherlands
3 Laboratory of Immunoregulation and Mucosal Immunology, Department of Molecular Biomedical Research, VIB, Technologypark 927, 9052 Ghent, Belgium

Correspondence should be addressed to Hermelijn H. Smits; h.h.smits@lumc.nl

Received 31 January 2013; Revised 15 March 2013; Accepted 16 March 2013

Academic Editor: Mohamad Mohty

Copyright © 2013 Anouk K. Gloudemans et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Allergic asthma is characterized by bronchial hyperresponsiveness, a defective barrier function, and eosinophilic lower airway inflammation in response to allergens. The inflammation is dominated by Th2 cells and IgE molecules and supplemented with Th17 cells in severe asthma. In contrast, in healthy individuals, allergen-specific IgA and IgG4 molecules are found but no IgE, and their T cells fail to proliferate in response to allergens, probably because of the development of regulatory processes that actively suppress responses to allergens. The presence of allergen-specific secretory IgA has drawn little attention so far, although a few epidemiological studies point at a reverse association between IgA levels and the incidence of allergic airway disease. This review highlights the latest literature on the role of mucosal IgA in protection against allergic airway disease, the mechanisms described to induce secretory IgA, and the role of (mucosal) dendritic cells in this process. Finally, we discuss how this information can be used to translate into the development of new therapies for allergic diseases based on, or supplemented with, IgA boosting strategies.

1. Introduction

Allergic asthma is a major health problem worldwide, causing episodes of wheezing, coughing, and breathlessness in susceptible individuals after repeated inhalation of harmless environmental allergens, such as house-dust mites (HDMs), molds, plant pollen, and animal dander [1, 2]. Currently approximately 300 million people worldwide suffer from asthma, with estimates suggesting that asthma prevalence increases globally by 50% every decade. Prevalence has reached a peak in developed countries, but rates are rising in developing regions (Africa, Latin America, and parts of Asia) as they become more westernized. This has reduced the global differences in prevalence; however, the global burden of asthma and allergies continues to rise, and new therapies are warranted [3, 4].

Interestingly, negative associations are found between the prevalence of allergic asthma and growing up on traditional European farms or rural tropical areas, usually exposed to higher ambient concentrations of microbial pollutants or higher rates of parasitic infections [5, 6]. Therefore, it was suggested that a reduced microbial exposure during childhood, due to changes in lifestyle, vaccination patterns, and/or improved hygiene, has contributed to the global increases in hyperinflammatory diseases. Insufficient microbial exposure may result in deficient maturation of the regulatory arm of the immune system, causing a disbalance of the immune system, allowing for uncontrolled expression of inflammatory responses against innocuous antigens later in life (“hygiene hypothesis”) [7].

Currently used medication against asthma is aimed at symptom relieve and does not restore this immune disbalance. As a consequence, treatment is chronic and sometimes resulting in severe side effects. New therapies should focus on reducing inflammatory responses against allergens at an early age preventing the onset of structural damage and changes to the lungs, by targeting natural tolerizing mechanisms as found in healthy individuals. In this review, we will focus on one of these mechanisms and describe the potential of inducing IgA responses by modulation of
2. Immune Responses against Allergens

2.1. Inflammatory Reactions against Inhaled Allergens in Allergic Asthma: Th2 Cells and IgE. Allergic asthma is a chronic inflammation of the airways controlled by effector Th2 cells and characterized by eosinophilic airway inflammation and high levels of allergen-specific IgE antibodies, hallmarks of a persistent Th2 response [2] (Figure 3(a)). Upon encounter with the allergen, effector responses can be divided into immediate and late phase reactions. The immediate allergic inflammatory reaction is initiated by crosslinking of IgE molecules which are bound to IgE receptors on basophils and mast cells. As a result, these cells will degranulate and release preformed mediators from vesicles or secrete cytokines (IL-6, TNFα, MIP1α) [9], causing immediate vascular permeability, blood vessel dilation, bronchoconstriction, and smooth muscle contraction [10]. This immediate reaction may be followed by the late phase response, initiated by inflammatory cytokines and type 2 cytokines, such as IL-4, IL-5, IL-9, and IL-13, which recruit and activate eosinophils and basophils and induce goblet cell metaplasia and overproduction of mucus [11, 12]. In severe forms of asthma, also Th17 cells are found, which enhance the effects of the Th2 cytokines and recruit neutrophils and other inflammatory leukocytes [13–15]. In addition to distortion of immunological pathways during allergen sensitization and challenge, also aberrant structural airway remodeling is involved in the development of asthma. Some groups have even suggested that the airway structural changes occur before the deranged immune response is present. Indeed, basement membrane thickening is detectable in children younger than three years old with persistent wheezing before the diagnosis of asthma [16, 17]. Airway remodeling includes marked changes in the airway wall, like epithelial injury, extracellular matrix deposition under the epithelial basal membrane, goblet cell hyperplasia, and increased smooth muscle mass. These changes lead to a defective physical and functional barrier of the airway epithelium in severe asthma. Various studies point at dysfunctional injury/repair mechanisms in response to damaging stimuli and/or respiratory viruses in asthmatics, which may only be in part explained by allergic airways inflammation [18, 19].

Dendritic cells (DCs) play a crucial role in the described processes leading to asthma pathogenesis (Figure 3(a)). Immature DCs reside in peripheral and mucosal tissues, such as the lungs, where they continuously sample the environment for foreign soluble antigens and small particles, including inhaled allergens [20, 21]. DCs express different types of pattern recognition receptors (PRRs), such as toll-like receptors (TLRs), NOD-like receptors, and C-type lectin receptors, that allow the recognition of different classes of molecules broadly shared by pathogens (pathogen-associated molecular patterns (PAMPs)) [22, 23]. Upon encounter of danger signals, DCs become activated and migrate to the draining lymph nodes [24], where they activate antigen-specific naïve Th cells and drive their development in effector T helper cells, such as Th1, Th2, Th17, or regulatory T (Treg) cells [25, 26]. Various studies have demonstrated that DCs are necessary for inducing allergic sensitization [27], for driving the development of Th2 immunity and eosinophilia [28–30], and are crucial for maintaining the inflammatory processes in the airways as well as bronchial hyperreactivity and chronic airway remodeling [31, 32]. After allergen uptake, the function of DCs is strongly influenced by signals encountered during their stay in the peripheral tissues, which can include microbial signals induced by the ligation of pattern recognition receptors (PRRs) on the DCs or alarming signals from structural cells like local epithelial cells of the airways [33–35]. Crosstalk between airway epithelial cells and DCs may form a critical link for the induction and continuation of allergic inflammation in the lungs as several EC-derived molecules can influence DC migration, differentiation, and function [20, 33, 36].

2.2. “Tolerizing” Immune Responses to Allergens in Healthy Individuals: Treg Cells and IgA. In healthy individuals, T-cell responses to allergens are commonly observed, yet are usually dominated by anergy or by regulatory T (Treg) cells that can suppress various effector Th cell subsets [37, 38]. Allergen-specific Treg cells can suppress Th2 cells by cell–cell contact or release of the anti-inflammatory and immunoregulatory cytokines IL-10 and transforming growth factor (TGF)-β. In almost all patients with asthma, one can find the counterregulatory Treg cells, but these fail to or insufficiently suppress allergic inflammation [39]. It has therefore been suggested that asthma may result from aberrant of defective Treg mechanisms.

Humoral responses of healthy individuals consist of mainly low IgG1, IgG4, and secretory IgA (sIgA) antibodies to allergens in the presence or absence of low amounts of IgE [37, 40, 41]. Although the presence of allergen-specific IgA has drawn relatively little attention so far, it is still unclear what its relative role is in the protection (or exacerbation) of allergic disease [42]. Although most individuals with immunoglobulin A (IgA) deficiency are asymptomatic, allergic disorders appear to be more common among patients with IgA deficiency [43]. Indeed, Balzar et al. found lower IgA levels in bronchoalveolar lavage of severe asthmatics than in healthy subjects, which correlated with lung function and asthma symptoms [44]. In contrast, high salivary secretory IgA levels were associated with less development of allergic symptoms in sensitized Swedish children [45]. Furthermore, high levels of specific IgA antibodies in salivary of sensitized infants were associated with significantly less late-onset wheezing [46]. In addition, allergic patients who naturally develop tolerance responses towards cow’s milk concomitantly undergo a shift towards IgA dominance in serum [47]. Moreover, in an experimental setting, Schwarz was able to protect mice against the development of eosinophilic airway inflammation and hyperresponsiveness by treating with antigen-specific IgA during challenge [48].

Taken together, these data show an inverse relationship between IgA and allergy development, suggesting a protective role for IgA in allergic diseases such as asthma.
3. Immunoglobulin A Antibodies and Its Functions

3.1. Isoforms and Receptors. The antibody IgA can occur as a monomer (Figures 1(a) and 1(b)), but also in dimeric or even polymeric forms through interactions with the joining chain (J-chain) (Figure 1(c)). All these different forms are mainly found in the circulation, while secretory IgA (sIgA) is only found at mucosal surfaces and is generated by the binding of dimeric IgA via the J-chain to the polymeric immunoglobulin receptor (pIgR) at the basolateral side of the epithelium which is subsequently transported to the luminal side (Figures 1(d) and 1(e)). Here, IgA is released at the mucosal surface (lumen) by cleavage from the pIgR. In this process part of the pIgR, called the secretory component (SC), remains attached to the IgA molecule, and together they form the molecule secretory IgA (SIgA). Mouse and human IgA biology differ in several aspects. In human serum, IgA occurs mainly in a monomeric form, while in mice polymeric IgA is the main isotype in serum. Furthermore, human IgA, but not mouse IgA, is divided into closely related subclasses, IgA1 and IgA2, of which the later one is less susceptible for proteolytic degradation (Figures 1(a) and 1(b)). In serum, the subclass IgA1 is dominant, while in secretions the main isoform found is IgA2, although both IgA1 and IgA2 can be detected as SlgA [49].

IgA has been described to interact with various host receptors, that is, pIgR, FcαRI (CD89), transferrin receptor (CD71), asialoglycoprotein receptor (ASGPR), and Fcγ/μR. The consequences after ligation are not very clear for most of these receptors. However, the FcαRI allows both inhibitory and activating signals and therefore is considered to be important for the role of IgA in preserving homeostasis and tolerance at mucosal sites [8, 50]. Moreover, FcαRI is the only IgA Fc receptor expressed on (blood) myeloid cells, including DCs, monocytes/macrophages, neutrophils, and eosinophils. In mucosal areas in steady state conditions, only few cells are positive for FcαRI. Intriguingly, this receptor has not been identified in mice. Although this receptor is associated with an immunoreceptor tyrosine-based activation motifs (ITAM), its signaling can be activating as well as inhibitory. This depends on the ligand and subsequent configuration (involving Syk or SHP-1 phosphatase) of the ITAM, resulting in an activating or an inhibitory ITAM motif. The inhibitory ITAM (ITAMI) pathway takes place in the absence of receptor coaggregation and of an immunoreceptor tyrosine-based inhibitory motif (ITIM), which is known for inhibiting immune responses. All forms of IgA can ligate to FcαRI, but they differ in their binding capacities. Monomeric IgA only binds with low affinity to the FcαRI and activates the ITAMI, which does not lead to cell activation or degranulation/oxidative burst (in the case of granulocytes) [51]. In contrast, IgA complexes show a stronger binding and subsequent activating signal, resulting in cell activation [52, 53].

3.2. Effector Functions of IgA. IgA is classically known for neutralizing toxins and bacteria (viruses) at mucosal surfaces [54, 55], by interfering with their motility, by competing for viscoelastic properties of the airway secretions [56]. The SC protects SlgA from proteolytic degradation and is involved in establishing local interactions with bronchial mucus, thereby contributing to the ”trapping” and removal of the antigen (“immune exclusion”) [57]. Interestingly, it has been suggested that IgA can also directly reduce inflammatory responses by inhibiting effector functions of inflammatory cells. For example, anti-FcαRI Fab treatment, by initiating ITAMI signaling, suppressed manifestations of allergic asthma in FcαRI transgenic mice immunized with anti-IgE immune complexes [58]. Triggering ITAMI signaling also prevented marked inflammation and leukocyte infiltration in kidney inflammation models such as glomerulonephritis [59]. Furthermore, in vitro crosslinking of FcαRI on human monocyte-derived DCs leads to internalization of IgA complexes and antigen presentation, resulting in DC maturation and IL-10 production...
(Serum) IgA ligation on monocytes also induces IL-10 expression [62] and inhibits inflammatory cytokine (IL-6 and TNFα) release [63, 64]. Importantly, IgA has only limited capacity to activate the complement system, in contrast to IgG and IgM. Furthermore, it can competitively block the IgG-mediated activation of complement [8, 65]. Of note, a few specific diseases are associated with an increase in serum IgA levels, often paralleled by IgA tissue deposition [66]. In IgA nephropathy, the formation of aggregated IgA immune complexes in the kidney causes severe inflammatory responses [67, 68]. However, there are indications that in these patients, glycosylation (e.g., sialylation) of the circulating IgA antibodies is abnormal, which may explain the pathogenic potential [53].

Collectively, these data suggest that under homeostatic conditions, secretory IgA contributes to the maintenance of mucosal tolerance by dampening immune responses. Therefore, IgA can have a role in preventing the development of hyperinflammatory responses towards environmental allergens that otherwise could cause allergic inflammation as observed in allergic rhinitis or asthma.

4. Regulation of Immunoglobulin A Responses

4.1. T-Cell-Dependent and T-Cell-Independent IgA Class Switching. Humoral responses in the mouse are mediated by at least three different subpopulations of mature B cells. These B cells can acquire the expression of various antibody isotypes, including IgA, by undergoing class switch recombination (CSR). In contrast to other isotypes, IgA class switching can occur both via a conventional T-Cell-dependent (TD) pathway and an alternative T-cell-independent (TI) pathway (Figure 2). Follicular (or B-2) B cells, located in the spleen, lymph nodes, and the Peyer’s Patches respond to T-cell engagement and need alternative costimulatory signals, such as CD40-CD40L, for TD class switching [81]; however, the respective role of B-1 or follicular B cells in the production of IgA has not been studied yet. The relative role of B-1 versus B-2 cells in IgA-mediated immunity is reviewed elsewhere [72].

Theoretically, it might be possible to induce in situ CSR of existing allergen-specific IgE+ B cells into IgA+ cells. Because Cα2 is the last exon located downstream from Cε in the human heavy chain locus, this may be the only alternative for CSR in IgE+ B cells. Shifting the allergen-specific antibody response from IgE to IgA2 would result in neutralization of allergen in the mucosal lumen, before it could interact with IgE, and could therefore constitute a therapeutic target. Although this has not been tested nor reported yet, based on the role of IL-21 and TGF-β in IgA class switching [81], they may contribute to induce IgA2 production in already class-switched B cells.

4.2. Role of Mucosal Dendritic Cells and TLRs. Mucosal conditioning of DCs occurs via resident tissue-derived factors, such as thymic stromal lymphopoietin (TSLP), IFN-β, RA, and TGF-β, but also by ligation of toll-like receptor (TLR) ligands expressed by (commensal) bacteria [82–84] (Figure 2). Epithelial cells release these DC conditioning factors in addition to other IgA stimulatory factors in response to TLR ligands [85]. In the gut lamina propria, several specialized DC subsets are described with an enhanced intrinsic capacity to drive IgA CSR. For example, Tip DCs express inducible nitric oxide synthase (iNOS) in response to TLR signaling and initiate TI IgA production by releasing BAFF and APRIL [86]. CD11c hi CD103 hi DCs induce TI IgA production upon sensing bacteria through TLR5, a process that elicits release of RA and IL-6 [87]. CD103+ DCs are known for driving the differentiation of FoxP3+ Treg cells. As the main RA
**Figure 2:** After conditioning by tissue-derived factors and TLR ligands, DCs activate T cells which provide for costimulatory signals (CD40-CD40L) and specific cytokines (TD), or DCs provide for alternative costimulatory signals, like BAFF and APRIL (TI) to initiate class switch recombination and expression of IgA by the mature B cells (IgA⁺ B cell). From the inductive site, the IgA⁺-B cells will migrate to the draining effector sites, where, in response to additional signals, they become plasma cells (PCs) and start to secrete IgA.

**Figure 3:** Crosstalk between epithelial cells and dendritic cells (DCs) in the lungs determines the balance between immunity and tolerance. (a) Allergen exposure in susceptible individuals may result in epithelial damage, initiating a cascade of immunological events leading to inflammation and allergic symptoms. (b) In contrast, IgA-inducing agents, such as CTB, alone or in combination with microbial exposure, prevent the development of allergic inflammation, by protecting the epithelial barrier and by effecting the function of various immune cells via DC. Immature DC (iDC), T helper 2 cell (Th2), T helper 17 cell (Th17), eosinophil (Eo), mast T-Cell (MC), and plasma cell (PC).
producing subset, they are also responsible for imprinting gut-homing molecules on B cells and support IgA synthesis [74]. How these DCs acquire their tolerogenic properties is not yet fully understood, but a role for microbial activation was suggested [88, 89]. Recently, it was published that in vitro mouse CD11b+ lung DCs induce IgA more efficiently than CD103+ lung DCs [90]. The use of CD11b as a marker for lung DCs is however confusing, as CD11b is not only found on a subset of conventional (c)DCs, but also on the population of monocyte-derived DCs (moDCs) that are recruited to the lungs at times of inflammation [91].

In addition to the conventional mouse DC subsets which drive IgA synthesis and are portrayed in the previous paragraph, also a plasmacytoid (p)DC subset has been described [92]. These pDCs differ from cDCs in expressing lower amounts of CD11c, yet they produce very high amounts of IFNα. Although both mouse gut lymph node-derived pDCs and cDCs were able to support B-cell IgA production, pDCs were more superior in vitro due to type 1 IFN dependent enhanced APRIL and BAFF expression [93]. Also in humans, IFNα producing pDCs seem to be more advanced in supporting B-cell proliferation and differentiation into antibody producing cells, including IgA, compared to myeloid DCs (mDC, grossly equivalent to mouse cDC subset) [94, 95].

Altogether DCs form a crucial cell type in the differentiation of IgA responses. Although by different mechanisms, both cDCs and pDCs can promote Ig responses, and their IgA inducing capacity can be enhanced by local factors produced by mucosal tissues as well as by (local) microbial products such as TLR ligands.

4.3. Early Priming and the Microbiota. The establishment of commensal flora in the intestine, and most likely also the respiratory tract [96], starts at birth and is considered to be crucial for stimulating and directing the development of the host immune system. Animals raised under germ-free conditions have an undeveloped immune system with fewer germinal centers and decreased number of IgA-producing plasma cells [97]. Interestingly, gut microbiota is necessary for a protective immune system, including mucosal IgA responses, in the airways. In response to OVA, germ-free (GF) mice developed more severe features of airway inflammation compared to control specific pathogen free (SPF) mice, which could be reversed by recolonization of GF mice with complex commensal flora. Furthermore, the absence of commensal bacteria was associated with less pDCs and attenuated production of IgA in the airways [98]. Human studies have also suggested the link between commensals and allergy. Indeed, children who developed allergy had significantly less diverse gut microbiota and lower levels of salivary SlgA [99], while, intestinal colonization by Staphylococcus aureus was associated with high circulating IgA levels and with a lower frequency of eczema [100]. The exact number and diversity of an individual’s community of commensals seem to be determined by factors occurring in early childhood [101]. Several mouse and human studies have shown that early life (prenatal, preconception) exposure to environments characterized by a diverse and concentrated microbial milieu such as traditional farming sites may protect against the development of allergic diseases [102–105]. Breast milk contains many IgA and may have a collective tolerogenic effect acting via slgA, cytokines, and/or immune complexes [106].

A rich microbial environment contributes to mucosal tolerance and protective IgA responses, which are associated with protection against allergic asthma. The ideal candidate for an adjuvant stimulating protective IgA responses and therefore preventing development of allergic asthma could therefore be a microbial-derived molecule.

5. Strategy for Allergy Intervention via Induction of IgA

5.1. Cholera Toxin B, an IgA Inducing Adjuvant. Cholera toxin is the most widely experimentally used mucosal adjuvant, potentiating serum and local immune responses to coadministered antigens [107]. The enterotoxin Cholera Toxin is produced by the bacterium Vibrio cholerae and consists of an A and B subunit, each with distinct effects on cells of the immune system. The A subunit is known for its toxic (side) effects: after entering the cell cytosol, the A subunit triggers electrolyte efflux via activation of adenylate cyclase and increased cyclic AMP (cAMP) production, resulting in severe watery diarrhea. The B subunit of CT (CTB) is more considered as a nontoxic subunit, as it is not linked to the activation of cAMP and its adjuvant activity seems to be mainly associated with immunoregulatory effects [107, 108]. For example, feeding of CTB conjugated to myelin basic protein before or after disease induction protected rats from experimental autoimmune encephalomyelitis [109], and nasal administration of CTB insulin significantly delayed incidence of spontaneous diabetes in NOD mice [110]. In these models, protection against autoimmunity by CTB/Ag conjugates was associated with the formation of Treg cells in these models, protection against autoimmunity by CTB/Ag conjugates was associated with the formation of Treg cells expressing IL-10 and/or TGF-β [109]. The tolerizing effect of CTB has also been shown to extend to other immunemediated diseases. In a delayed type hypersensitivity model, (prolonged) oral treatment with low doses of OVA conjugated to CTB prevented sensitization and suppressed IgE antibody responses in sensitized mice [111]. Furthermore, intranasal pretreatment of CTB linked to the BetV1, a major allergen of birch pollen, prevented sensitization to the antigen by shifting the Th2 response towards Th1 and the induction of allergen-specific IgA responses [112]. Likewise, we found that CTB administration in the lungs stimulates local secrety IgA responses which protected against the development of allergic airway inflammation (AAI), while mice deficient for both cDCs and not so much pDCs, while adoptive transfer of in vitro generated CTB treated DCs was sufficient to enhance IgA responses in mouse lungs [113]. Interestingly, the primary action of CTB as an adjuvant may be primarily mediated through a direct effect on APCs such as DCs. Upon in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly effected in vivo administration, CTB mainly ef
in vitro experiments suggest that asynergy between CTB and MyD88-dependent TLR signals selectively imprints an IgA inducing phenotype in DCs, characterized by RALDH1 and TGF-β expression [114]. Upon exposure to CTB in vivo, ALDH activity was mainly enhanced in the CD11b+ DCs, which may include mo-DCs (Figure 3(b)). Also the experiments with the bone marrow-derived DCs differentiated in GM-CSF, which are a good model for these inflammatory DCs, may suggest that (CD11b+) moDCs could be responsible for CTB-induced IgA responses in the mouse airways. This is certainly a possibility as CTB seems to work best at inducing IgA responses when accompanied by some degree of LPS. LPS is a known trigger of moDC recruitment [115]. Until we have more specific depleting antibodies or transgenic mouse strains to selectively deplete moDCs, we can however only speculate at this stage whether this is true.

If we are to exploit the full potential of IgA as an immunomodulatory immunoglobulin in allergic asthma and other immune mediated diseases, the role of different DC subsets in the regulation of humoral IgA responses and modulation by adjuvants should be studied in more detail.

5.2. Allergen-Specific Immunotherapy. Allergen-specific immunotherapy (SIT) represents the only curative treatment of allergic diseases currently available and involves the incremental delivery of the allergen to the individual which is sensitive [116]. Successful IT components of the regulatory network such as Treg cells and the cytokine IL-10 are elevated, while allergen-specific IgE levels are reduced. It is hypothesized that the enhanced immunoregulatory network is instrumental in suppressing allergen-specific effector T cells which are responsible for many of the characteristics of allergic diseases. IL-10 does not only contribute to T-Cell tolerance but also potently suppresses total and allergen-specific IgE, and it simultaneously increases IgG4 and IgA production in cultures [117, 118]. Interestingly, successful immunotherapy is also associated with increases in IgA responses in vivo. In a 2-year double blind trial, grass-pollen immunotherapy induced a shift in allergen-specific antibody response towards IgA2, which correlated with increased local TGF-β expression and induced monocyte IL-10 expression [119]. Another study using sublingual grass-pollen immunotherapy (SLIT) reported increases in allergen-specific IgG4 and IgA [120].

In its current form, SIT has major drawbacks and cannot compete with treatment on the basis of symptom relief (antihistamines and corticosteroids) for many asthma patients. High concentrations of allergen extract need to be administered on a long term (~5 years) and regular basis. This introduces a risk of potentially life-threatening allergic reactions [121]. Therefore, it might be interesting to apply the use of tolerogenic adjuvants, specifically inducing Treg cells and/or secretory IgA to improve efficacy and safety of SIT. For example, when the allergen is coupled to the adjuvant CTB, it will be efficiently targeted to the DC [113], allowing the use of lower allergen doses and decreasing the risk of anaphylactic shocks. Future experiments in mouse models for true allergens, like birch pollen or house-dust mite, experimental SIT models, and (cells from) allergic patients will need to point out the usefulness of application of the class of “mucosal” adjuvants in current SIT protocols.

5.3. Boosting IgA as a Preventive Strategy. The establishment of commensal flora in the intestine and respiratory tract starts at birth and is considered to be crucial for stimulating and directing the development of the host immune system, including the mucosal IgA response [97, 122, 123]. In our in vitro coculture system, we confirmed the role for microbial-derived TLR ligands in the conditioning of DCs for stimulating IgA responses. Interestingly, the mucosal adjuvant CTB does not only enhance IgA induction by TLR-ligand primed DCs, but also initiates IgA production in the case of low dose exposure to MyD88-activating signals which are insufficient to induce IgA on their own [114]. This is interesting considering the hypothesis that decreased or altered microbial exposure associated with an affluent life style is contributing to the increase in asthma prevalence during the last decades. Only recently we have started to appreciate the importance of the microbiota on human health, and restoring or manipulating disrupted host-microbiota relationship has become a potent strategy for treating inflammatory diseases, including asthma [124]. CTB could contribute to broad antibody repertoire and sufficient mucosal IgA levels in people with impaired or delayed IgA synthesis, by reducing the threshold for microbial signals or providing the necessary cosignals, to maintain mucosal immunity and local homeostasis (Figure 3).

It was shown that children who developed allergy had less diverse (gut and airway) microbiota [99] and decreased serum or mucosal IgA responses [45, 46, 100] compared to healthy controls. Studies that measured IgA levels at different time points showed an increase over time which may be due to microbial exposure and microbiota development [45, 100]. Especially during the first months and year, events such as mode of birth delivery, type of “first” milk (breast versus formula milk), and microbial exposure will determine the composition of microbiota [122]. This suggests that particularly during this early period in life impaired IgA responses may allow for sensitization and/or development of allergic symptoms. By the time that allergic (asthma) patients have reached adulthood, impaired IgA responses may be restored to normal levels, but the “damage” has already occurred and allergen-specific inflammatory responses have developed. Indeed, in a cohort of adult allergic asthmatic patients, we did not find reduced (secretory) IgA levels in nasal washes compared to nonallergic controls (Gloudeams et al., unpublished observations). Alternatively, in a fraction of the allergic infants with a slowly developing mucosal IgA repertoire, allergy symptoms may relieve together with the establishment of a fully developed IgA response. Thus, one should keep in mind that the association between IgA and asthma may be misinterpreted using an adult cohort.

6. Words of Caution

The effector function of IgA is very much depending on local (inflammatory) factors present and needs to be carefully examined before applying IgA enhancing therapy. For
example, IgA immune complexes bind with stronger affinity, subsequently resulting in cell activation and elimination of the pathogen [52, 53]. In certain cases, IgA complexes can even cause severe inflammation and pathology, like in immune complex glomerulonephritis [68, 125]. Importantly, eosinophils and neutrophils express receptors for IgA that can activate the cells upon binding of IgA immune complexes [51, 126], resulting in activation and/or degranulation of the cell [50, 127]. Therefore, also in severe asthma, where in addition to eosinophils also neutrophils are important mediators, IgA may aggravate the inflammation instead of promoting tolerance. Interestingly, both in patients with IgA nephropathy and in patients with asthma, abnormal glycosylation of the IgA antibody or the FcαRI receptor was found, which may allow exacerbated immune responses and disease development instead [128, 129].

In addition to the isomorph of IgA and local tissue factors, reactivity or specificity of the antibody will determine the receptor binding affinity and thus the immunological effect of Ig-receptor ligation. Primitive or polyreactive (natural) IgA antibodies are sufficient to protect the host from excess mucosal immune stimulation by harmless commensal bacteria and may protect against some noninvasive parasites [130, 131]. However, affinity maturation of IgA is necessary to provide protection from more invasive commensal bacteria and from true pathogens. Thus, there seems to be a correlation between the “sophistication” of the IgA response and the aggressiveness of the subsequent immune response, at least in the gut [132]. However, it still remains unclear how this applies for environmental particles in the lung, such as inhaled allergens. Therefore, to evaluate the efficacy of IgA-based treatment against allergic diseases, not only the level of mucosal IgA responses need to be carefully studied in health and disease, but also aspects such as the affinity and reactivity of the antibodies should be taken into account.

Although local IgA induction during specific immunotherapy may have potential to improve the treatment of allergic airway inflammation, based on the dynamics of the development of IgA responses in life and the functional duality of the IgA-receptor interaction, it seems essential to stimulate IgA responses under noninflammatory conditions. Therefore, we hypothesize that the development of protective mucosal IgA responses will occur best in the context of a homeostatic environment, through the activation of dedicated mDCs and/or mo-DCs, aiming at the induction of a fully developed mucosal IgA repertoire in time and preventing the development of inflammatory responses to allergens (Figure 3).

**Acknowledgment**

This work was supported by a Grant from the Netherlands Asthma Foundation (NAF 3.2.06.043).

**References**

[1] P. J. Barnes, “Immunology of asthma and chronic obstructive pulmonary disease,” *Nature Reviews Immunology*, vol. 8, no. 3, pp. 183–192, 2008.

[2] S. T. Holgate, “Innate and adaptive immune responses in asthma,” *Nature Medicine*, vol. 18, no. 5, pp. 673–683, 2012.

[3] N. Pearce, N. Ait-Khaled, R. Beasley et al., “Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC),” *Thorax*, vol. 62, no. 9, pp. 757–765, 2007.

[4] S. S. Braman, “The global burden of asthma,” *Chest*, vol. 130, supplement 1, pp. 4S–12S, 2006.

[5] H. H. Smits, B. Everts, F. C. Hartgers, and M. Yazdanbakhsh, “Chronic helminth infections protect against allergic diseases by active regulatory processes,” *Current Allergy and Asthma Reports*, vol. 10, no. 1, pp. 3–12, 2010.

[6] E. von Mutius and D. Vercelli, “Farm living: effects on childhood asthma and allergy,” *Nature Reviews Immunology*, vol. 10, no. 12, pp. 861–868, 2010.

[7] B. Schaub, R. Lauener, and E. von Mutius, “The many faces of the hygiene hypothesis,” *Journal of Allergy and Clinical Immunology*, vol. 117, no. 5, pp. 969–977, 2006.

[8] J. M. Woof and M. W. Russell, “Structure and function relationships in IgA,” *Mucosal Immunology*, vol. 4, no. 6, pp. 590–597, 2011.

[9] J. P. Kinet, “The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology,” *Annual Review of Immunology*, vol. 17, pp. 931–972, 1999.

[10] M. Wills-Karp, “Immunologic basis of antigen-induced airway hyperresponsiveness,” *Annual Review of Immunology*, vol. 17, pp. 255–281, 1999.

[11] M. Dullaers, B. R. De, F. Ramadani, H. J. Gould, P. Gevaert, and B. N. Lambrecht, “The who, where, and when of IgE in allergic airway disease,” *The Journal of Allergy and Clinical Immunology*, vol. 129, no. 3, pp. 635–645, 2012.

[12] A. B. Kay, “Allergy and allergic diseases. First of two parts,” *The New England Journal of Medicine*, vol. 344, no. 1, pp. 30–37, 2001.

[13] L. Cosmi, F. Liotta, E. Maggi, S. Romagnani, and F. Annunziato, “Th7 cells: new players in asthma pathogenesis,” *Allergy*, vol. 66, no. 8, pp. 989–998, 2011.

[14] Y. H. Wang and M. Wills-Karp, “The potential role of interleukin-17 in severe asthma,” *Current Allergy and Asthma Reports*, vol. 11, no. 5, pp. 388–394, 2011.

[15] W. Al-Ramli, D. Préfontaine, E. Chouial et al., “TH17-associated cytokines (IL-17A and IL-17F) in severe asthma,” *Journal of Allergy and Clinical Immunology*, vol. 123, no. 5, pp. 1185–1187, 2009.

[16] S. Sglagliani, D. N. Payne, J. Zhu et al., “Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers,” *American Journal of Respiratory and Critical Care Medicine*, vol. 176, no. 9, pp. 858–864, 2007.

[17] K. Malmstrom, A. S. Pelkonen, P. L. Malmberg et al., “Lung function, airway remodelling and eosinophilic inflammation in preschool wheezers,” *Thorax*, vol. 66, no. 2, pp. 157–162, 2011.

[18] S. T. Holgate, “The sentinel role of the airway epithelium in asthma pathogenesis,” *Immunological Reviews*, vol. 242, no. 1, pp. 205–219, 2011.

[19] B. N. Lambrecht and H. Hammad, “The airway epithelium in asthma,” *Nature Medicine*, vol. 18, no. 5, pp. 684–692, 2012.

[20] H. Hammad and B. N. Lambrecht, “Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma,” *Nature Reviews Immunology*, vol. 8, no. 3, pp. 193–204, 2008.

[21] N. Novak and T. Bieber, “Dendritic cells as regulators of immune response and tolerance,” *Journal of Allergy and Clinical Immunology*, vol. 121, supplement 2, pp. S370–S374, 2008.
[22] S. Akira, S. Uematsu, and O. Takeuchi, “Pathogen recognition and innate immunity,” *Cell*, vol. 124, no. 4, pp. 783–801, 2006.

[23] M. Idzko, H. Hammad, M. van Nimwegen et al., “Extracellular NatureReviews Immunology,” vol. 5, no. 8, pp. 617–628, 2005.

[24] K. Shortman and Y. J. Liu, “Mouse and human dendritic cell subsets,” *Nature Reviews Immunology*, vol. 2, no. 3, pp. 151–161, 2002.

[25] C. Reis e Sousa, “Dendritic cells in a mature age,” *Nature Reviews Immunology*, vol. 6, no. 6, pp. 476–483, 2006.

[26] B. N. Lambrecht and H. Hammad, “Taking our breath away: dendritic cells in the pathogenesis of asthma,” *Nature Reviews Immunology*, vol. 3, no. 12, pp. 994–1003, 2003.

[27] H. Hammad, M. Plantinga, K. Deswarte et al., “Inflammatory dendritic cells—not basophils—are necessary and sufficient for induction of Th2 immunity to inhaled house dust mite allergen,” *Journal of Experimental Medicine*, vol. 207, no. 10, pp. 2097–2111, 2010.

[28] B. N. Lambrecht, M. De Veerman, A. J. Coyle, J. C. Gutierrez-Ramos, K. Thielemans, and R. A. Pauwels, “Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation,” *Journal of Clinical Investigation*, vol. 106, no. 4, pp. 551–559, 2000.

[29] B. N. Lambrecht, B. Salomon, D. Klatzmann, and R. A. Pauwels, “Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice,” *Journal of Immunology*, vol. 160, no. 8, pp. 4090–4097, 1998.

[30] L. S. van Rijt, S. Jung, A. Kleinjan et al., “In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma,” *Journal of Experimental Medicine*, vol. 201, no. 6, pp. 981–991, 2005.

[31] L. S. van Rijt, N. Vos, M. Willart et al., “Persistent activation of dendritic cells after resolution of allergic airway inflammation breaks tolerance to inhaled allergens in mice,” *American Journal of Respiratory and Critical Care Medicine*, vol. 4, no. 3, pp. 303–311, 2011.

[32] M. A. Willart, K. Deswarte, P. Pouliot et al., “Interleukin-1alpha controls allergens and their role in the allergic immune response,” *Immunological Reviews*, vol. 242, no. 1, pp. 51–68, 2011.

[33] M. Jutel, M. Akdis, F. Budak et al., “IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy,” *European Journal of Immunology*, vol. 33, no. 5, pp. 1205–1214, 2003.

[34] C. M. Lloyd and C. M. Hawrylowicz, “Regulatory T Cells in Asthma,” *Immunity*, vol. 31, no. 3, pp. 438–449, 2009.

[35] M. Akdis, “Immune tolerance in allergy,” *Current Opinion in Immunology*, vol. 21, no. 6, pp. 700–707, 2009.

[36] S. Barberi, M. P. Villa, G. B. Pajno et al., “Immune response to sublingual immunotherapy in children allergic to mites,” *Journal of Biological Regulators & Homeostatic Agents*, vol. 25, no. 4, pp. 627–634, 2011.

[37] C. Pilette, S. R. Durham, J. P. Vaerman, and Y. Sibille, “Mucosal immunity in asthma and chronic obstructive pulmonary disease: a role for immunoglobulin A?” *Proc Am Thorac Soc*, vol. 1, no. 2, pp. 125–135, 2004.

[38] L. Yel, “Selective IgA deficiency,” *Journal of Clinical Immunology*, vol. 30, no. 1, pp. 10–16, 2010.

[39] S. Balzar, M. Strand, T. Nakano, and S. E. Wenzel, “Subtle immunodeficiency in severe asthma: IgA and IgG2 correlate with lung function and symptoms,” *International Archives of Allergy and Immunology*, vol. 140, no. 2, pp. 96–102, 2006.

[40] M. Fageras, S. Tomicic, T. Voor, B. Bjorksten, and M. C. Jenmalm, “Slow salivary secretory IgA maturation may relate to low microbial pressure and allergic symptoms in sensitized children,” *Pediatric Research*, vol. 70, no. 6, pp. 572–577, 2011.

[41] A. Sandin, B. Björkstén, M. F. Böttcher, E. Englund, M. C. Jenmalm, and L. Bräbeck, “High salivary secretory IgA antibody levels are associated with less late-onset wheezing in IgE-sensitized infants,” *Pediatric Allergy and Immunology*, vol. 22, no. 5, pp. 477–481, 2011.

[42] G. B. G. Sletten, R. Halvorsen, E. Eagaas, and T. S. Halstensen, “Casein-specific immunoglobulins in cow’s milk allergic patient subgroups reveal a shift to IgA dominance in tolerant patients,” *Pediatric Allergy and Immunology*, vol. 18, no. 1, pp. 71–80, 2007.

[43] J. Schwarze, G. Cieslewicz, A. Joetham et al., “Antigen-specific immunoglobulin-A prevents increased airway responsiveness and lung eosinophilia after airway challenge sensitized mice,” *American Journal of Respiratory and Critical Care Medicine*, vol. 158, no. 2, pp. 519–525, 1998.

[44] J. M. Woof and M. A. Ken, “The function of immunoglobulin A in immunity,” *Journal of Pathology*, vol. 208, no. 2, pp. 270–282, 2006.

[45] B. D. Wines and P. M. Hogarth, “IgA receptors in health and disease,” *Tissue Antigens*, vol. 68, no. 2, pp. 103–114, 2006.

[46] K. R. Bartemes, K. M. Cooper, K. L. Drain, and H. Kitai, “Secretory IgA induces antigen-independent eosinophil survival and cytokine production without inducing effector functions,” *Journal of Allergy and Clinical Immunology*, vol. 116, no. 4, pp. 827–835, 2005.

[47] J. E. Bakema and E. M. van, “The human immunoglobulin A Fc receptor FcαRIα: a multifaceted regulator of mucosal immunity,” *Mucosal Immunology*, vol. 4, no. 6, pp. 612–624, 2011.

[48] R. C. Monteiro, “The role of IgA and IgA Fc receptors as anti-inflammatory agents,” *Journal of Clinical Immunology*, vol. 30, supplement 1, pp. S61–S64, 2010.

[49] R. C. Williams and R. J. Gibbons, “Inhibition of bacterial adherence by secretory immunoglobulin A: a mechanism of antigen disposal,” *Science*, vol. 177, no. 4050, pp. 697–699, 1972.

[50] M. B. Mazanec, J. G. Nedrud, C. S. Kaetzel, and M. E. Lamm, “A three-tiered view of the role of IgA in mucosal defense,” *Immunology Today*, vol. 14, no. 9, pp. 430–435, 1993.
K.olas, H. Butterweck, W. Teschner, H. P. Schwarz, and B. M. Reipert, “Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells,” *Clinical and Experimental Immunology*, vol. 140, no. 3, pp. 478–490, 2010.

G. Pfaffenbach, M. E. Lamm, and I. Gigli, “Activation of the guinea pig alternative complement pathway by mouse IgA immune complexes,” *Journal of Experimental Medicine*, vol. 155, no. 1, pp. 231–247, 1982.

D. L. Delacruz, K. B. Elkon, and A. P. Geubel, “Changes in size, subclass, and metabolic properties of serum immunoglobulin A in liver diseases and in other diseases with high serum immunoglobulin A,” *Journal of Clinical Investigation*, vol. 71, no. 2, pp. 358–367, 1983.

B. D. Oortwijn, J. W. Eigenraam, M. P. Rastaldi, A. Roos, M. R. Daha, and C. van Kooten, “The role of secretory IgA and complement in IgA nephropathy,” *Seminars in Nephrology*, vol. 28, no. 1, pp. 58–65, 2008.

I. C. Moura, M. Benhamou, P. Launay, F. Vrtovsnik, U. Blank, and R. C. Monteiro, “The glomerular response to IgA deposition in IgA nephropathy,” *Seminars in Nephrology*, vol. 28, no. 1, pp. 88–95, 2008.

A. Cerutti, M. Cols, M. Gentile et al., “Regulation of mucosal IgA responses: lessons from primary immunodeficiencies,” *Annals of the New York Academy of Sciences*, vol. 1238, pp. 132–144, 2011.

A. Chorny, I. Puga, and A. Cerutti, “Innate signaling networks in mucosal IgA class switching,” *Advances in Immunology C*, vol. 107, pp. 31–69, 2010.

A. J. MacPherson, K. D. McCoy, F. E. Johansen, and P. Brandtzæg, “The immune geography of IgA induction and function,” *Mucosal Immunology*, vol. 1, no. 1, pp. 11–22, 2008.

K. Suzuki, M. Maruya, S. Kawamoto, and S. Fagarasan, “Roles of B-1 and B-2 cells in innate and acquired IgA-mediated immunity,” *Immunological Reviews*, vol. 237, no. 1, pp. 180–190, 2010.

O. Garraud, G. Borhis, G. Badr et al., “Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond,” *BMC Immunology*, vol. 13, p. 63, 2012.

J. R. Mora, M. Iwata, B. Eksteen et al., “Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells,” *Science*, vol. 314, no. 5802, pp. 1157–1160, 2006.

T. Naito, T. Suda, K. Suzuki et al., “Lung dendritic cells have a potent capability to induce production of immunoglobulin A,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 38, no. 2, pp. 161–167, 2008.

D. A. Kaminski and J. Stallnerer, “Enhanced IgA class switching in marginal zone and B1 B cells relative to follicular/B2 B cells,” *Journal of Immunology*, vol. 177, no. 9, pp. 6025–6029, 2006.

F. G. M. Kroese, R. De Waard, and N. A. Bos, “B-1 cells and their reactivity with the murine intestinal microflora,” *Seminars in Immunology*, vol. 8, no. 1, pp. 11–18, 1996.

A. J. Macpherson, D. Gatto, E. Sainsbury, G. R. Harriman, H. Hengartner, and R. M. Zinkernagel, “A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria,” *Science*, vol. 288, no. 5474, pp. 2222–2226, 2000.

M. C. Thurnheer, A. W. Zuercher, J. J. Cebra, and N. A. Bos, “B1 cells contribute to serum IgM, but not to intestinal IgA, production in gnotobiotic Ig allotype chimeric mice,” *Journal of Immunology*, vol. 170, no. 9, pp. 4564–4571, 2003.

Y. S. Choi and N. Baumgarth, “Dual role for B-1a cells in innate and acquired IgA-mediated immunity,” *Immunology and Cell Biology*, vol. 88, no. 2, pp. 161–167, 2008.

K. Suzuki and S. Fagarasan, “How host-bacterial interactions lead to IgA synthesis in the gut,” *Trends in Immunology*, vol. 29, no. 11, pp. 523–531, 2008.

H. Tezuka and T. Ohteki, “Regulation of intestinal homeostasis by dendritic cells,” *Immunological Reviews*, vol. 234, no. 1, pp. 247–258, 2010.

B. He, W. Xu, P. A. Santini et al., “Intestinal bacteria trigger T cell-independent immunoglobulin A2 class switching by inducing epithelial-cell secretion of the cytokine APRIL,” *Immunity*, vol. 26, no. 6, pp. 812–826, 2007.

H. Tezuka, Y. Abe, M. Iwata et al., “Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells,” *Nature*, vol. 448, no. 7156, pp. 929–933, 2007.

S. Uematsu, K. Fujimoto, M. H. Jang et al., “Regulation of humoral and cellular gut immunity by lamina propria dendritic
cells expressing Toll-like receptor 5,” Nature Immunology, vol. 9, no. 7, pp. 769–776, 2008.

[88] J. L. Coombe, K. R. R. Siddiqui, C. V. Arancibia-Cárcamo et al., “A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta -and retinoic acid-dependent mechanism,” Journal of Experimental Medicine, vol. 204, no. 8, pp. 1757–1764, 2007.

[89] C. L. Scott, A. M. Aumeunier, and A. M. Mowat, “Intestinal microbiota in early infancy: composition and development,” Acta Paediatrica, International Journal of Paediatrics, Supplement, vol. 91, no. 441, pp. 48–55, 2003.

[90] M. I. Lundell, B. Hesselmar, I. Nordström et al., “High circulating immunoglobulin A levels in infants are associated with intestinal toxigenic Staphylococcus aureus and a lower frequency of eczema,” Clinical and Experimental Allergy, vol. 39, no. 5, pp. 662–670, 2009.

[91] S. Fanaro, R. Chierici, P. Guerrini, and V. Vigi, “Intestinal microflora in early infancy: composition and development,” Acta Paediatrica, International Journal of Paediatrics, Supplement, vol. 91, no. 441, pp. 48–55, 2003.

[92] M. L. Conrad, R. Fersrl, R. Teich et al., “Maternal TLR signaling is required for prenatal asthma protection by the nonpathogenic microbe Acinetobacter lwofii F78,” Journal of Experimental Medicine, vol. 206, no. 13, pp. 2869–2877, 2009.

[93] M. J. Ege, M. Mayer, A. C. Normand et al., “Exposure to environmental microorganisms and childhood asthma,” The New England Journal of Medicine, vol. 364, no. 8, pp. 701–709, 2011.

[94] J. Riedler, C. Braun-Fahrlander, W. Eder et al., “Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey,” The Lancet, vol. 358, no. 9288, pp. 1129–1133, 2001.

[95] D. G. Peroni, G. L. Piacentini, A. Bodini, R. Pigozzi, and A. L. Boner, “Transforming growth factor-beta is elevated in unpasteurized cow’s milk,” Pediatric Allergy and Immunology, vol. 20, no. 1, pp. 42–44, 2009.

[96] V. Verhasselt, “Neonatal tolerance under breastfeeding influence,” Current Opinion in Immunology, vol. 22, no. 5, pp. 623–630, 2010.

[97] J. Holmgren, J. Adamsson, F. Anjüere et al., “Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA,” Immunology Letters, vol. 97, no. 2, pp. 181–188, 2005.

[98] N. A. Williams, T. R. Hirst, and T. O. Nashar, “Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic,” Immunology Today, vol. 20, no. 2, pp. 95–101, 1999.

[99] J. B. Sun, C. Czerkinsky, and J. Holmgren, “Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit,” Scandinavian Journal of Immunology, vol. 71, no. 1, pp. 1–11, 2009.

[100] C. Aspord and C. Thivolet, “Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice,” Clinical and Experimental Immunology, vol. 130, no. 2, pp. 204–211, 2002.

[101] C. Rask, J. Holmgren, M. Fredriksson et al., “Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice,” Clinical and Experimental Allergy, vol. 30, no. 7, pp. 1024–1032, 2000.

[102] M. Bublin, E. Hoflehner, B. Wagner et al., “Use of a genetic cholera toxin B subunit/allergen fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses,” Vaccine, vol. 25, no. 50, pp. 8395–8404, 2007.

[103] H. H. Smits, A. K. Gloudemans, M. van Nimwegen et al., “Cholera toxin B suppresses allergic inflammation through induction of secretory IgA,” Mucosal Immunology, vol. 2, no. 4, pp. 331–339, 2009.

[104] A. K. Gloudemans, M. Plantinga, M. Guiliams et al., “The mucosal adjuvant cholera toxin B instructs non-mucosal dendritic cells to promote IgA production via retinoic acid and TGF-beta,” PLoS ONE, vol. 8, no. 3, Article ID 59822, 2013.

[105] C. Cheong, I. Matos, J. H. Choi et al., “Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209+ dendritic cells for immune T cell areas,” Cell, vol. 143, no. 3, pp. 416–429, 2010.

[106] C. M. Lloyd and J. R. Murdoch, “Tolerizing allergic responses in the lung,” Mucosal Immunology, vol. 3, no. 4, pp. 334–344, 2010.

[107] R. Aalberse, “The role of IgG antibodies in allergy and immunotherapy,” Allergy, vol. 66, supplement 95, pp. 28–30, 2011.

[108] C. A. Akdis and M. Akdis, “Mechanisms of allergen-specific immunotherapy,” Journal of Allergy and Clinical Immunology, vol. 127, no. 1, pp. 18–27, 2011.
[119] C. Pilette, K. T. Nouri-Aria, M. R. Jacobson et al., “Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression,” *Journal of Immunology*, vol. 178, no. 7, pp. 4658–4666, 2007.

[120] G. W. Scadding, M. H. Shamji, M. R. Jacobson et al., “Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells,” *Clinical and Experimental Allergy*, vol. 40, no. 4, pp. 598–606, 2010.

[121] D. I. Bernstein, M. Wanner, L. Borish, and G. M. Liss, “Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001,” *Journal of Allergy and Clinical Immunology*, vol. 113, no. 6, pp. 1129–1136, 2004.

[122] C. L. Johnson and J. Versalovic, “The human microbiome and its potential importance to pediatrics,” *Pediatrics*, vol. 129, no. 5, pp. 950–960, 2012.

[123] J. C. Clemente, L. K. Ursell, L. W. Parfrey, and R. Knight, “The impact of the gut microbiota on human health: an integrative view,” *Cell*, vol. 148, no. 6, pp. 1258–1270, 2012.

[124] B. Bjorksten, “Diverse microbial exposure-consequences for vaccine development,” *Vaccine*, vol. 30, no. 29, pp. 4336–4340, 2012.

[125] B. D. Oortwijn, J. W. Eijkenraam, M. P. Rastaldi, A. Roos, M. R. Daha, and C. van Kooten, “The role of secretory IgA and complement in IgA nephropathy,” *Seminars in Nephrology*, vol. 28, no. 1, pp. 58–65, 2008.

[126] M. van Egmond, C. A. Damen, A. B. van Spriel, G. Vidarsson, E. van Garderen, and J. G. J. van de Winkel, “IgA and the IgA Fc receptor,” *Trends in Immunology*, vol. 22, no. 4, pp. 205–211, 2001.

[127] V. Decot, G. Woerly, M. Loyens et al., “Heterogeneity of expression of IgA receptors by human, mouse, and rat eosinophils,” *Journal of Immunology*, vol. 174, no. 2, pp. 628–635, 2005.

[128] R. C. Monteiro, R. W. Hostoffer, M. D. Cooper, J. R. Bonner, G. L. Gartland, and H. Kubagawa, “Definition of immunoglobulin A receptors on eosinophils and their enhanced expression in allergic individuals,” *Journal of Clinical Investigation*, vol. 92, no. 4, pp. 1681–1685, 1993.

[129] R. C. Monteiro, “Role of IgA and IgA Fc receptors in inflammation,” *Journal of Clinical Immunology*, vol. 30, no. 1, pp. 1–9, 2010.

[130] N. L. Harris, I. Spoerri, J. F. Schopfer et al., “Mechanisms of neonatal mucosal antibody protection,” *Journal of Immunology*, vol. 177, no. 9, pp. 6256–6262, 2006.

[131] K. D. McCoy, M. Stoel, R. Stettler et al., “Polyclonal and specific antibodies mediate protective immunity against enteric helminth infection,” *Cell Host and Microbe*, vol. 4, no. 4, pp. 362–373, 2008.

[132] E. Slack, M. L. Balmer, J. H. Fritz, and S. Hapfemeier, “Functional flexibility of intestinal IgA-broadening the fine line,” *Frontiers in Immunology*, vol. 3, p. 100, 2012.